Press Releases

Date   Headline
Sep 02, 2015 Department of Defense Awards Cleveland BioLabs a $9.2 Million Contract for Advanced Development of Entolimod as a Medical Radiation Countermeasure
Sep 02, 2015 Cleveland BioLabs to Present at Rodman & Renshaw 17th Annual Global Investment Conference
Aug 18, 2015 Cleveland BioLabs Announces New Patents Strengthening Entolimod Portfolio
Aug 12, 2015 Cleveland BioLabs Reports Second Quarter 2015 Financial Results and Development Progress
Jul 31, 2015 Cleveland BioLabs Announces Date Change for Second Quarter 2015 Financial Results
Jul 21, 2015 Cleveland BioLabs to Report Second Quarter 2015 Financial Results on August 3
Jul 16, 2015 Cleveland BioLabs Announces Receipt of Letter From Nasdaq Confirming Compliance With Minimum Stockholders' Equity Requirement
Jul 13, 2015 Cleveland BioLabs Announces Results of Phase 1 Study of CBLB612 in Russian Federation
Jul 10, 2015 Cleveland BioLabs Announces Board Appointments
Jul 09, 2015 Cleveland BioLabs Closes Private Placement With Strategic Investor for $25 Million Equity Financing
Jun 25, 2015 Cleveland BioLabs Enters Into Private Placement Agreement With Strategic Investor for $25 Million Equity Financing
Jun 15, 2015 Cleveland BioLabs Submits Pre-EUA Dossier for Entolimod to FDA
Jun 01, 2015 Cleveland BioLabs Releases Entolimod Phase 1 Study Findings at ASCO
May 06, 2015 Cleveland BioLabs Reports First Quarter 2015 Financial Results and Development Progress
May 05, 2015 Cleveland BioLabs Announces Appointment of Biotechnology Industry Veteran, Langdon Miller, MD, as President and Chief Medical Officer
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue